Revolution Medicines (NASDAQ:RVMD – Free Report) had its price objective upped by Needham & Company LLC from $31.00 to $35.00 in a research note published on Wednesday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock. Other research analysts have also issued reports about the company. HC Wainwright reaffirmed a buy rating and set a $32.00 target price on shares of Revolution Medicines in a research report on Wednesday, April 12th. JPMorgan Chase & Co. lowered their target price on Revolution Medicines from $38.

https://www.dailypolitical.com/2023/08/06/revolution-medicines-nasdaqrvmd-pt-raised-to-35-00.html

#dailypolitical